Country star Morgan Wallen has been dropped by a number of radio stations after a video leaked of him using racial slurs during a rowdy night out.
Country star Morgan Wallen has been dropped by a number of radio stations after a video leaked of him using racial slurs during a rowdy night out.
Shares from Asia to Europe gained on Wednesday, as a retreat in U.S. Treasury yields fuelled demand for riskier assets from oil to bitcoin and kept the dollar pinned down. The Euro STOXX 600 added 0.5%, with Frankfurt shares climbing 1% to a record high and London's FTSE gaining 1.1% before the UK's new budget is introduced, with measures to boost the economy. Euro zone government bond yields were little changed, with the benchmark German 10-year Bund yield flat at -0.34%.
Rishi Sunak has pledged to do ‘whatever it takes’ to help people and businesses through the coronavirus crisis.
MONTREAL, March 03, 2021 (GLOBE NEWSWIRE) -- At its meeting held on March 2, 2021, the Board of Directors of the Laurentian Bank of Canada (TSX: LB) (the “Bank”) declared a regular quarterly dividend of 40 cents per share on the common shares payable on May 1, 2021 to the holders of record at the close of business on April 1, 2021. The above-mentioned dividends are designated as eligible dividends for the purposes of the Income Tax Act (Canada) and any similar provincial and territorial legislation. The above-mentioned shares are eligible shares under the Bank’s Shareholder Dividend Reinvestment and Share Purchase Plan (the “Plan”). Consequently, the holders of such shares may elect to reinvest their dividends in newly issued common shares of the Bank. Such purchases will be made at the applicable investment price as defined in the Plan, less a discount of 2%, and no brokerage commissions or service charges of any kind will apply. In addition, holders of such shares are entitled to make monthly optional cash payments to purchase additional common shares in accordance with the terms of the Plan. For more information, please contact Computershare Trust Company of Canada at 1-800-564-6253. Beneficial or non-registered owners of common and preferred shares must contact their financial institution or broker for instructions on how to participate in the Plan. About Laurentian Bank Financial Group Founded in 1846, Laurentian Bank Financial Group is a diversified financial services provider whose mission is to help its customers improve their financial health. The Laurentian Bank of Canada and its entities are collectively referred to as Laurentian Bank Financial Group (the “Group” or the “Bank”). With more than 2,900 employees guided by the values of proximity, simplicity and honesty, the Group provides a broad range of advice-based solutions and services to its personal, business and institutional customers. With pan-Canadian activities and a presence in the U.S., the Group is an important player in numerous market segments. The Group has $45.2 billion in balance sheet assets and $29.2 billion in assets under administration. Information: Fabrice TremblayAdvisor, CommunicationsOffice: 514 284-4500, extension 40020Mobile: 438 firstname.lastname@example.org
UK contactless payment limit to rise to £100Move, to be announced by Rishi Sunak in the budget, may not be rolled out until later this year The limit on tap-and-go card spending was increased to £45 last year as retailers sought ways to cut the need for physical contact in shops amid the Covid pandemic. Photograph: Bloomberg via Getty Images
SoftBank aims to double user numbers at its PayPay QR code payment app in the next three to four years, an executive at its domestic internet subsidiary Z Holdings told Reuters on Wednesday, as it seeks to extend its lead in cashless payments. PayPay has used SoftBank's sales network and aggressive rebates to attract 36 million users in the three years since launch, driving a shift to push Japanese consumers to digital payments away from their traditional preference for cash. "We want to double the user base during the investment phase," Z Holdings co-CEO Kentaro Kawabe said in a joint interview with fellow co-CEO Takeshi Idezawa.
Cyprus plans to launch a register in coming months identifying the owners of thousands of companies on the island, lifting a veil of secrecy on opaque and complex corporate structures that campaigners say can help criminals seeking to hide their loot. Details of thousands of companies domiciled on the island, many thought to have Russian links, will be collected from March 16 to be entered in a so-called Ultimate Beneficial Owner (UBO) register. Supporters say the register, a requirement of European Union anti-money laundering (AML) regulations, could be a game changer for Cyprus, which activists say has in the past been a magnet for those concealing wealth behind brass plate companies, lured by competitive tax rates.
Northern Trust today announced it has been selected by Osmosis Investment Management (Osmosis) to provide fund administration, global custody and depositary services for the Osmosis Resource Efficient Core Equity (ex-fossil fuels) Fund in a Collective Investment in Transferable Securities (UCITS) Common Contractual Fund (CCF).
ROCHESTER, Mich., March 03, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has been invited to present at the 33rd Annual ROTH Growth Conference being held virtually on March 15-17, 2021. The conference will feature presentations from public and private companies across a variety of industry sectors, followed by one-on-one and small group meetings, as well as expert panels and fireside chats. Past events have featured more than 550 participating companies and drawn more than 5,000 attendees that include institutional investors, analysts, family offices and high-net-worth investors. OptimizeRx pre-recorded video webcast presentation is available today here and via the investor relations section of the company’s website at www.optimizerx.com. OptimizeRx CEO, Will Febbo, will participate in one-on-one meetings with investors and analysts during the conference. He plans to discuss the company’s recently reported record 2020 results, with a 76% increase in revenue to $43.3 million largely driven by what is seen as a permanent shift to more digital enablement. The company also finished the year with a sales pipeline of more than $180 million, including enterprise deals valued at more than $50 million. To submit a registration request, click here. To schedule a one-on-one meeting with OptimizeRx, please contact your ROTH representative. For any questions about the company, contact Ron Both of CMA at (949) 432-7557 or submit your request here. About ROTH Capital PartnersROTH Capital Partners, LLC “ROTH” is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately held and employee owned. For more information on ROTH, please visit www.roth.com. About OptimizeRxOptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement. For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com. Important Cautions Regarding Forward-Looking Statements This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks. OptimizeRx ContactDoug Baker, CFOTel (248) 651-6568 email@example.com Media Relations ContactMaira Alejandra, Media Relations ManagerTel (754) firstname.lastname@example.org Investor Relations ContactRon Both, CMATel (949) 432-7557Email Contact
Arab foreign ministers on Wednesday reappointed veteran Egyptian diplomat as the secretary general of the Cairo-based Arab League, Egypt’s state-run news agency reported. Ahmed Aboul Gheit, a former ambassador to the United Nations and Egypt’s last foreign minister under ousted president Hosni Mubarak, won the backing of the Arab foreign ministers meeting in Cairo, MENA's report said. In January, Egypt’s President Abdel Fattah el-Sissi announced that Cairo would nominate Aboul Gheit for a second, five-year term as the chief of the 22-member bloc.
President Biden announced the "type of collaboration between companies we saw in World War Two," with two competitors working together. Merck will help Johnson & Johnson produce its COVID vaccine,...
Literally add some pep to your step
The Maine senator is the first Republican to support Biden's historic pick to lead the federal agency with oversight of public lands and tribal obligations.
The financial information reported herein is based on the condensed interim consolidated (unaudited) information for the three-month period ended January 31, 2021, and has been prepared in accordance with International Financial Reporting standards (IFRS), as issued by the International Accounting Standards Board (IASB). All amounts are denominated in Canadian dollars. The Laurentian Bank of Canada and its entities are collectively referred to as Laurentian Bank Financial Group (the “Group” or the “Bank”) and provide deposit, investment, loan, securities, trust and other products or services. Highlights of first quarter 2021 Adjusted net income(1) of $47.6 million for the first quarter of 2021, compared with $36.9 million for the first quarter of 2020.Reported net income of $44.8 million for the first quarter of 2021, compared with $32.2 million for the first quarter of 2020.Adjusted diluted earnings per share(1) of $1.03 for the first quarter of 2021, compared with $0.79 for the first quarter of 2020.Diluted earnings per share of $0.96 for the first quarter of 2021, compared with $0.68 for the first quarter of 2020. MONTREAL, March 03, 2021 (GLOBE NEWSWIRE) -- Laurentian Bank Financial Group reported net income of $44.8 million and diluted earnings per share of $0.96 for the first quarter of 2021, compared with $32.2 million and $0.68 for the first quarter of 2020. Return on common shareholders' equity was 7.1% for the first quarter of 2021, compared with 5.0% for the first quarter of 2020. On an adjusted basis, net income was $47.6 million and diluted earnings per share were $1.03 for the first quarter of 2021, up from $36.9 million and $0.79 for the first quarter of 2020. Adjusted return on common shareholders' equity was 7.5% for the first quarter of 2021, compared with 5.8% a year ago. Reported results include adjusting items, as detailed in the Non-GAAP and Key Performance Measures section. “I am pleased to report that we had a good start to the year. Our results were driven by a strong performance in capital market activities, the resumption of growth in commercial banking and our strong cost discipline.” said Rania Llewellyn, President and Chief Executive Officer. “We will take the experiences of the past year to propel us forward, as we renew our leadership team and create an organization that is agile, efficient and above all customer centric.” For the three months endedIn millions of Canadian dollars, except per share and percentage amounts (Unaudited)January 31, 2021 January 31, 2020 VarianceReported basis Net income$44.8 $32.2 39%Diluted earnings per share$0.96 $0.68 41%Return on common shareholders’ equity7.1% 5.0% Efficiency ratio70.4% 79.1% Common Equity Tier 1 capital ratio9.8% 9.0% Adjusted basis(1) Adjusted net income$47.6 $36.9 29%Adjusted diluted earnings per share$1.03 $0.79 30%Adjusted return on common shareholders’ equity7.5% 5.8% Adjusted efficiency ratio68.9% 76.6% (1)Certain measures presented throughout this document exclude amounts designated as adjusting items and are Non-GAAP measures. Refer to the Non-GAAP measures section for further details Consolidated Results Non-GAAP measures Management uses both generally accepted accounting principles (GAAP) and non-GAAP measures to assess the Bank’s performance. Results prepared in accordance with GAAP are referred to as “reported” results. Non-GAAP measures presented throughout this document are referred to as “adjusted” measures and exclude amounts designated as adjusting items. Adjusting items relate to restructuring plans and to business combinations and have been designated as such as management does not believe they are indicative of underlying business performance. Non-GAAP measures are considered useful to readers in obtaining a better understanding of how management analyzes the Bank’s results and in assessing underlying business performance and related trends. Non-GAAP measures do not have any standardized meaning prescribed by GAAP and are unlikely to be comparable to any similar measures presented by other issuers. The following table shows adjusting items and their impact on reported results. For the three months endedIn thousands of Canadian dollars, except per share amounts (Unaudited)January 31, 2021 October 31, 2020 January 31, 2020Impact on income before income taxes Reported income before income taxes$56,511 $41,647 $34,679 Adjusting items, before income taxes Restructuring charges(1) Severance charges262 2,253 2,838 Other restructuring charges359 1,909 (104) 621 4,162 2,734 Items related to business combinations Amortization of net premium on purchased financial instruments(2)— 100 232 Amortization of acquisition-related intangible assets(3)3,073 3,180 3,399 3,073 3,280 3,631 3,694 7,442 6,365 Adjusted income before income taxes$60,205 $49,089 $41,044 Impact on net income Reported net income$44,819 $36,811 $32,172 Adjusting items, net of income taxes Restructuring charges(1) Severance charges193 1,659 2,086 Other restructuring charges264 1,402 (76) 457 3,061 2,010 Items related to business combinations Amortization of net premium on purchased financial instruments(2)— 77 171 Amortization of acquisition-related intangible assets(3)2,296 2,362 2,547 2,296 2,439 2,718 2,753 5,500 4,728 Adjusted net income$47,572 $42,311 $36,900 Impact on diluted earnings per share Reported diluted earnings per share$0.96 $0.79 $0.68 Adjusting items Restructuring charges(1)0.01 0.07 0.05 Items related to business combinations0.05 0.06 0.06 0.06 0.13 0.11 Adjusted diluted earnings per share(4)$1.03 $0.91 $0.79 (1)Restructuring charges mainly result from the optimization of the Quebec Retail Network operations and the related streamlining of certain back-office and corporate functions. In 2020, restructuring charges also resulted from the reorganization of retail brokerage activities and other measures aimed at improving efficiency. Restructuring charges include severance charges, salaries, provisions, communication expenses and professional fees and charges related to lease contracts. Restructuring charges are included in Non-interest expenses.(2)Amortization of net premium on purchased financial instruments resulted from a one-time gain on a business acquisition in 2012 and is included in the Amortization of net premium on purchased financial instruments line item.(3)Amortization of acquisition-related intangible assets results from business acquisitions and is included in the Non-interest expenses line item.(4)The impact of adjusting items on a per share basis may not add due to rounding. Three months ended January 31, 2021 financial performance Net income was $44.8 million and diluted earnings per share were $0.96 for the first quarter of 2021, compared with $32.2 million and $0.68 for the first quarter of 2020. Adjusted net income was $47.6 million for the first quarter of 2021 up 29% from $36.9 million for the first quarter of 2020, and adjusted diluted earnings per share were $1.03, up 30% compared with $0.79 for the first quarter of 2020. Total revenue Total revenue was $247.4 million for the first quarter of 2021, up 4% compared with $238.7 million for the first quarter of 2020. Net interest income increased by $4.3 million to $173.1 million for the first quarter of 2021, compared with $168.8 million for the first quarter of 2020. The increase was mainly due to improved funding costs, mostly as the utilization of secured funding increased, as well as to higher prepayment penalties on residential mortgage loans. Net interest margin was 1.84% for the first quarter of 2021, an increase of 3 basis points compared with the first quarter of 2020, essentially for the same reasons. Other income increased by $4.4 million or 6% to $74.3 million for the first quarter of 2021, compared with $69.9 million for the first quarter of 2020. The increase was mainly due to the strong contribution from capital market activities, which improved by $7.8 million compared with the first quarter of 2020. This was partly offset by a decrease in service charges and VISA card service revenues due to ongoing changes to the retail banking environment, exacerbated by the COVID-19 pandemic. Provision for credit losses The provision for credit losses amounted to $16.8 million for the first quarter of 2021 compared with $14.9 million for the first quarter of 2020, an increase of $1.9 million. The increase year-over-year was mainly due to an increase in allowances on impaired commercial loans. Refer to the “Risk Management” section of the MD&A and to Note 5 to the Condensed Interim Consolidated Financial Statements for more information on provision for credit losses and allowances for credit losses. Non-interest expenses Non-interest expenses amounted to $174.1 million for the first quarter of 2021, a decrease of $14.8 million or 8% compared with the first quarter of 2020. Adjusted non-interest expenses amounted to $170.4 million for the first quarter of 2021, a decrease of $12.4 million or 7% compared with the first quarter of 2020. Salaries and employee benefits amounted to $95.4 million for the first quarter of 2021, essentially unchanged compared with the first quarter of 2020. Year-over-year, higher performance-based compensation related to strong capital market activities was mostly offset by a decrease in salaries reflecting the headcount reduction implemented in 2020. Premises and technology costs were $48.5 million for the first quarter of 2021, a decrease of $1.3 million compared with the first quarter of 2020, mainly as a result of continued efforts to streamline costs, as well as a slowdown of the pace of IT projects. Other non-interest expenses were $29.6 million for the first quarter of 2021, a decrease of $11.6 million compared with the first quarter of 2020. The improvement mainly resulted from lower regulatory costs, as well as lower advertising, business development and travel expenses, ensuing from efficiency measures and current economic conditions. Restructuring charges were $0.6 million for the first quarter of 2021 and mainly included severance charges and professional fees. Efficiency ratio The adjusted efficiency ratio was 68.9% for the first quarter of 2021, compared with 76.6% for the first quarter of 2020, as a result of lower adjusted expenses and an increase in total revenue. Adjusted operating leverage was positive year-over-year. The efficiency ratio on a reported basis was 70.4% for the first quarter of 2021, compared with 79.1% for the first quarter of 2020, as a result of lower expenses and an increase in total revenue. Income taxes For the quarter ended January 31, 2021, the income tax expense was $11.7 million, and the effective tax rate was 20.7%. The lower tax rate, compared to the statutory rate, is attributed to a lower taxation level of revenue from foreign operations, as well as from the favourable effect of holding investments in Canadian securities that generate non-taxable dividend income. For the quarter ended January 31, 2020, income tax expense was $2.5 million, and the effective tax rate was 7.2%. Year-over-year, the higher income tax rate is mainly attributed to the proportionally higher domestic income. Financial Condition As at January 31, 2021, total assets amounted to $45.2 billion, a 2% increase from $44.2 billion as at October 31, 2020, mostly due to the higher level of liquid assets. Liquid assets Liquid assets consist of cash, deposits with banks, securities and securities purchased under reverse repurchase agreements. As at January 31, 2021, these assets totalled $10.5 billion, an increase of $0.9 billion compared with $9.6 billion as at October 31, 2020. The Bank continues to prudently manage its level of liquid assets. The Bank's funding sources remain well diversified and sufficient to meet all liquidity requirements. Liquid assets represented 23% of total assets as at January 31, 2021, compared with 22% as at October 31, 2020. Loans Loans and bankers’ acceptances, net of allowances, stood at $33.0 billion as at January 31, 2021, unchanged compared with the level as at October 31, 2020. During the first quarter of 2021, commercial loan growth resumed, which was offset by reductions in personal loans and residential mortgage loans. Commercial loans and acceptances amounted to $13.2 billion as at January 31, 2021, an increase of 3% since October 31, 2020. Growth in inventory financing volumes resumed in the quarter, reflecting seasonality as dealers begin to restock their inventories despite continued supply chain challenges. Real estate lending also contributed to growth and continued to show resilience during the COVID-19 pandemic amidst the lower interest rate environment. Personal loans amounted to $4.0 billion as at January 31, 2021, a decrease of $0.1 billion or 4% since October 31, 2020, mainly as a result of the continued reduction in the investment loan portfolio, reflecting the continued reduction in the use of leverage by consumers. Residential mortgage loans amounted to $16.1 billion as at January 31, 2021, a decrease of $0.2 billion or 1% since October 31, 2020. The acquisition of mortgage loans from third parties, as part of the Bank's program to optimize the usage of the National Housing Act mortgage-backed securities allocations, has contributed to mitigating the impact of other repayments. Deposits Deposits decreased by $0.3 billion or 1% to $23.6 billion as at January 31, 2021 compared with $23.9 billion as at October 31, 2020, mainly as the Bank optimized its funding sources to align with its asset level. Personal deposits stood at $18.3 billion as at January 31, 2021, down $0.5 billion compared with October 31, 2020. The decrease resulted mainly from lower term deposits sourced through intermediaries managed down as the Bank increased its debt related to securitization activities to optimize funding costs as described below, partly offset by higher volumes of demand deposits generated through the various direct to customer distribution channels of the Bank. Business and other deposits increased by $0.2 billion over the same period to $5.3 billion, mostly due to an increase in wholesale funding as the Bank took advantage of favourable market conditions to augment its term funding. Personal deposits represented 77% of total deposits as at January 31, 2021, compared with 79% as at October 31, 2020, and contributed to the Bank's good liquidity position. Debt related to securitization activities Debt related to securitization activities increased by $0.4 billion or 4% compared with October 31, 2020 and stood at $10.6 billion as at January 31, 2021. Since the beginning of the year, mortgage loan securitization through the CMHC programs, supplemented by other secured funding, more than offset maturities of liabilities related to the Canada Mortgage Bond program, as well as normal repayments. Shareholders’ equity and regulatory capital Shareholders’ equity amounted to $2,644.9 million as at January 31, 2021, compared with $2,611.2 million as at October 31, 2020. Compared to October 31, 2020, retained earnings increased by $44.3 million as the net income contribution of $44.8 million and other gains related to employee benefit plans and equity securities designated at fair value through other comprehensive income of $19.9 million were partly offset by dividends amounting to $20.4 million. Accumulated other comprehensive income decreased by $14.3 million, essentially as a result of a reduction in the cumulative foreign currency translation amount. For additional information, please refer to the Consolidated Statement of Changes in Shareholders' Equity in the Condensed Interim Consolidated Financial Statements. The Bank’s book value per common share was $54.42 as at January 31, 2021 compared to $53.74 as at October 31, 2020. The Common Equity Tier 1 capital ratio stood at 9.8% as at January 31, 2021, compared with 9.6% as at October 31, 2020. The increase compared with October 31, 2020 mainly results from internal capital generation. This level of capital provides the Bank with the necessary operational flexibility to resume growth and to pursue key initiatives prudently, considering the economic conditions. Caution Regarding Forward-Looking Statements The Bank may, from time to time, make written or oral forward-looking statements within the meaning of applicable securities legislation, including in this document and the documents incorporated by reference herein, and in other documents filed with Canadian regulatory authorities or in other written or oral communications. Forward-looking statements include, but are not limited to, statements regarding business plans and strategies, priorities and financial objectives, the regulatory environment in which the Bank operates, the anticipated impact of the coronavirus (“COVID-19”) pandemic on the Bank’s operations, earnings results and financial performance and statements under the headings “Outlook”, “COVID-19 Pandemic” and “Risk Appetite and Risk Management Framework” contained in the Bank's 2020 Annual Report, including the Management’s Discussion and Analysis for the fiscal year ended October 31, 2020 and other statements that are not historical facts. Forward-looking statements typically are identified with words or phrases such as “believe”, “assume”, “estimate”, “forecast”, “outlook”, “project”, “vision”, “expect”, “foresee”, “anticipate”, “plan”, “goal”, “aim”, “target”, “may”, “should”, “could”, “would”, “will”, “intend” or the negative of these terms, variations thereof or similar terminology. By their very nature, forward-looking statements require us to make assumptions and are subject to inherent risks and uncertainties, both general and specific in nature. Material economic assumptions underlying the forward-looking statements contained in this document are set out in the 2020 Annual Report under the heading “Outlook”. There is significant risk that the predictions, forecasts, projections or conclusions will prove to be inaccurate, that the Bank's assumptions may not be correct, and that actual results may differ materially from such predictions, forecasts, projections or conclusions. The Bank cautions readers against placing undue reliance on forward-looking statements, as a number of factors, many of which are beyond its control and the effects of which can be difficult to predict, could influence, individually or collectively, the accuracy of the forward-looking statements and cause actual future results to differ significantly from the targets, expectations, estimates or intentions expressed in the forward-looking statements. These factors include, but are not limited to risks relating to: the impacts of the COVID-19 pandemic on the Bank, its business, financial condition and prospects; technology, information systems and cybersecurity; technological disruption, competition and its ability to execute on its strategic objectives; the economic climate in the U.S. and Canada; accounting policies, estimates and developments; legal and regulatory compliance; fraud and criminal activity; human capital; insurance; business continuity; business infrastructure; environmental and social risk and climate change; and its ability to manage operational, regulatory, legal, strategic, reputational and model risks, all of which are described in more detail in the section titled “Risk Appetite and Risk Management Framework” beginning on page 43 of the 2020 Annual Report including the Management’s Discussion and Analysis for the fiscal year ended October 31, 2020. The Bank further cautions that the foregoing list of factors is not exhaustive. Additional risks and uncertainties not currently known to us or that the Bank currently deems to be immaterial may also have a material adverse effect on its financial position, financial performance, cash flows, business or reputation. Any forward-looking statements contained in this document represent the views of Management only as at the date hereof, are presented for the purposes of assisting investors and others in understanding certain key elements of the Bank’s current objectives, strategic priorities, expectations and plans, and in obtaining a better understanding of the Bank’s business and anticipated operating environment and may not be appropriate for other purposes. The Bank does not undertake to update any forward-looking statements, whether oral or written, made by the Bank or on its behalf whether as a result of new information, future events or otherwise, except to the extent required by securities regulations. Additional information relating to the Bank can be located on the SEDAR website at www.sedar.com. Access to Quarterly Results Materials This press release can be found on our website at www.lbcfg.ca, under the Press Room tab, and our Report to Shareholders, Investor Presentation and Supplementary Financial Information under the Investor Centre tab, Financial Results. Conference Call Laurentian Bank Financial Group invites media representatives and the public to listen to the conference call to be held at 9:00 a.m. (ET) on March 3, 2021. The live, listen-only, toll-free, call-in number is 1-800-239-9838, code 9371678. A live webcast will also be available on the Group’s website under the Investor Centre tab, Financial Results. The conference call playback will be available on a delayed basis from 1:00 p.m. (ET) on March 3, 2021 until 12:00 p.m. (ET) on April 2, 2021, on our website under the Investor Centre tab, Financial Results. The presentation material referenced during the call will be available on our website under the Investor Centre tab, Financial Results. Contact InformationInvestor RelationsMediaSusan CohenFabrice TremblayDirector, Investor RelationsAdvisor, CommunicationsMobile: 514 970-0564Office: 514 284-4500, ext. email@example.comMobile: 438 989-6070 firstname.lastname@example.org About Laurentian Bank Financial Group Founded in 1846, Laurentian Bank Financial Group is a diversified financial services provider whose mission is to help its customers improve their financial health. The Laurentian Bank of Canada and its entities are collectively referred to as Laurentian Bank Financial Group (the “Group” or the “Bank”). With more than 2,900 employees guided by the values of proximity, simplicity and honesty, the Group provides a broad range of advice-based solutions and services to its personal, business and institutional customers. With pan-Canadian activities and a presence in the U.S., the Group is an important player in numerous market segments. The Group has $45.2 billion in balance sheet assets and $29.2 billion in assets under administration.
SunOpta Inc. ("SunOpta" or the "Company") (Nasdaq:STKL) (TSX:SOY), a leading healthy food and beverage company focused on plant-based foods and beverages and fruit-based foods and beverages, today announced financial results for the fourth quarter ended January 2, 2021.
Las Vegas, Nevada--(Newsfile Corp. - March 3, 2021) - Cyber Apps World Inc. (OTC Pink: CYAP) ("Cyber Apps" or the "Company") (Cyberappsworld.com), an acquirer and developer of innovative cyber technologies with the potential for disruptive scalability and eventual spin-off success, is pleased to announce that the Company is currently in late-stage negotiations with a software development firm for the acquisition of a technology solution geared toward management of remote workers with an emphasis on ...
PARSIPPANY, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2021 Barclays Global Healthcare Conference at 10:55 AM ET on Tuesday, March 9, 2021. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About Pacira Pacira BioSciences, Inc. (Nasdaq: PCRX) is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera°® system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com. CONTACT: Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.email@example.com
RESEARCH TRIANGLE PARK, N.C., March 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two investor conferences in March. Jack Bailey, G1’s Chief Executive Officer, will provide a presentation during the HC Wainwright Global Life Sciences Conference; this presentation will be available starting on March 9, 2021 at 7:00 AM ET. In addition, Mr. Bailey will also participate in a fireside chat during the Roth 33rd Annual Conference on March 17, 2021 at 10:30 AM ET. These conferences are being held virtually, and webcasts will be accessible on the Events & Presentations page of http://www.g1therapeutics.com. About G1 TherapeuticsG1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics. Contacts:Will RobertsVice President, Investor Relations & Corporate Communications919-907-1944 firstname.lastname@example.org
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will present at two upcoming virtual investor conferences. H.C. Wainwright Global Life Sciences ConferenceMarch 9-10, 2021An on-demand corporate presentation from Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, will be available starting at 7:00 am EST (1:00 pm CET) on March 9, 2021. A webcast of the event will be accessible on the InflaRx website in the Investors section under Events & Presentations. Oppenheimer 31st Annual Healthcare ConferenceTuesday, March 16, 2021 at 8:00 am EST (1:00 pm CET)A live webcasted corporate presentation from Prof. Riedemann will be available on the InflaRx website in the Investors section under Events & Presentations. A replay of the presentation will be accessible on InflaRx’s website following the live event. About InflaRx N.V.: InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information please visit www.inflarx.com. Contacts: InflaRx N.V.Jordan Zwick – Chief Strategy OfficerEmail: IR@inflarx.deTel: +1 917-338-6523 MC Services AGKatja Arnold, Laurie Doyle, Andreas JungferEmail: email@example.comEurope: +49 89-210 2280US: +1-339-832-0752 FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials; the impact of the COVID-19 pandemic on the Company; the timing and our ability to commence and conduct clinical trials; potential results from current or potential future collaborations; our ability to make regulatory filings, obtain positive guidance from regulators, and obtain and maintain regulatory approvals for our product candidates; our intellectual property position; our ability to develop commercial functions; expectations regarding clinical trial data; our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies; the industry in which we operate; the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in InflaRx’s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
Coty to Partner With LanzaTech to Pioneer New Sustainable Fragrance Production
According to the [190+ Pages] research study; the global Hair Transplant Market in 2019 was approximately USD 5,612.89 Million. The market is expected to grow at a CAGR of 22.1% and is anticipated to reach around USD 25,116.67 Million by 2026. Top market players are Bosley, Restoration Robotics Inc., MEDICAMAT, Cole Instruments Inc. and others.New York, NY, March 03, 2021 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled “Hair Transplant Market By Surgery Method (Single Follicular Unit Transplantation (FUT), Follicular Unit Extraction (FUE) and Others), By Surgical Type (Headhair Transplant, Eyebrow Transplant, Frontal Hairline Lowering or Reconstruction and Others) By distribution channel (Hospital, Tricology Clinics, Dermatological Clinics, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2026”. “According to the research study, the global Hair Transplant Market was estimated at USD 5,612.89 Million in 2019 and is expected to reach USD 25,116.67 Million by 2026. The global Hair Transplant Market is expected to grow at a compound annual growth rate (CAGR) of 22.1% from 2019 to 2026”. A hair transplant is a kind of surgical technique that involved the removal of hair follicles from one part of the body to the affected part of the body. The site where hairs get removed called donor sites and the place where this hair is used called recipient sites. Due to the beneficial effect of hair transplantation compared to other methods, these methods not only prefers for people suffering from hair loss but also for those who want to alter their hairlines or acquire an attractive look. Donor sites can be any part of the body like, Face, Legs, Head, and others. Request Your Free Sample Report of Hair Transplant Market @ https://www.fnfresearch.com/sample/hair-transplant-market-by-surgery-method-single-follicular-949 (The free sample of this report is readily available on request). Our Free Sample Report Includes: 2020 Updated Report Introduction, Overview, and In-depth industry analysisCOVID-19 Pandemic Outbreak Impact Analysis Included190+ Pages Research Report (Inclusion of Updated Research)Provide Chapter-wise guidance on Request2020 Updated Regional Analysis with Graphical Representation of Size, Share & TrendsIncludes Updated List of table & figuresUpdated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue AnalysisFacts and Factors research methodology (Note: The sample of this report is updated with COVID-19 impact analysis before delivery) Key Questions Answered in this Report 1) What was the impact of COVID-19 on the Hair Transplant Market? 2) What is the market size, share of the Hair Transplant Market? 3) Who are the top market players in Hair Transplant Market? 4) What will be the future market of the Hair Transplant Market? Key Offerings: Market Size & Forecast by Revenue | 2020−2026Market Dynamics – Leading trends, growth drivers, restraints, and investment opportunitiesMarket Segmentation – A detailed analysis by product, by types, end-user, applications, segments, and geographyCompetitive Landscape – Top key vendors and other prominent vendors Inquire more about this report before purchase @ https://www.fnfresearch.com/inquiry/hair-transplant-market-by-surgery-method-single-follicular-949 (You may enquire a report quote OR available discount offers to our sales team before purchase.) Impact Analysis of COVID-19 Pandemic on Businesses: Know Short Term and Long Term Impact Most of the businesses are facing a growing litany of business-critical concerns related to the coronavirus outbreak, including supply chain disruptions, a risk of a recession, and a potential drop in consumer spending. All these scenarios will play out differently across various regions and industries, making accurate and timely market research more essential than ever. We at Facts and Factors (http://www.fnfresearch.com) understand how difficult it is for you to plan, strategize, or make business decisions, and as such, we have your back to support you in these uncertain times with our research insights. Our team of consultants, analysts, and experts has developed an analytical model tool for markets that helps us to assess the impact of the virus more effectively on the industrial markets. We are further implementing these insights into our reports for a better understanding of our clients. Request COVID-19 Impact Analysis on Businesses: https://www.fnfresearch.com/sample/hair-transplant-market-by-surgery-method-single-follicular-949 The market is driven by an increasing number of hair loss cases across the world. In addition, the rising prevalence of guided baldness among genders across the world is one of the major drivers which helps in the growth of the market. Furthermore, keen public interest followed by increasing per capita expenditures in healthcare across the world is the major driving factor for this market. The high cost of treatment and lack of facility is one of the major restraint factors affecting the growth of the market. Continuous research and development may help to create futuristic opportunities within the forecast periods. Industry Major Market Players MEDICAMAT Restoration Robotics Inc. Cole Instruments Inc. Bernstein Medical Ethics hair Instruments Bosley To know an additional revised 2020 list of market players, request a sample report: https://www.fnfresearch.com/sample/hair-transplant-market-by-surgery-method-single-follicular-949 In product type, the market is classified into Single Follicular Unit Transplantation (FUT), Follicular Unit Extraction (FUE), and others. Single Follicular Unit Transplantation (FUT) acquires the largest market share in the year 2019. This segment acquires more than half of the global hair transplant market. The growth is accounted for due to patient with hair baldness is larger in number. Follicular unit transplantation is a hair restoration technique where patients are transplanted in a group of 1 to 4 hairs in the patients. Based on surgery type, the market is in-depth fragmented into four types: Eyebrow Transplant, Head hair Transplant, Frontal Hairline Lowering or Reconstruction, and Others. The head hair Transplant segment is the largest market in the year 2019. The Head has a widely affected region. People show a keen interest in the restoration of hair in this region. Based on end-users, the market is classified into hospitals, Trico logy Clinics, Dermatological Clinics, and Others. The dermatological clinic holds the largest percentage of patients of hair transplants in the year 2019. Dermatological Clinic is an institution providing better help related to skin and skin-related disorders. These segments account for around more than 40% of market shares in the year 2019. Directly Purchase a copy of the report with TOC @ https://www.fnfresearch.com/buynow/su/hair-transplant-market-by-surgery-method-single-follicular-949 The report study further includes an in-depth analysis of industry players' market shares and provides an overview of leading players' market position in the Hair Transplant sector. Key strategic developments in the Hair Transplant market competitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other noteworthy activities by key players of the Hair Transplant market are appropriately highlighted in the report. The Hair Transplant market size is estimated to develop with healthy CAGR in upcoming years. Hair Transplant has a wide application that leads to the growth of the industry. Nonetheless, lack of knowledge is likely to obstruct the market in the coming years. Request Customized Copy of Report @ https://www.fnfresearch.com/customization/hair-transplant-market-by-surgery-method-single-follicular-949 (We customize your report according to your research need. Ask our sales team for report customization.) The global Hair Transplant market has been segmented on the basis of product, end-user, and application. On the basis of product segment, the target market is segmented into Single Follicular Unit Transplantation (FUT), Follicular Unit Extraction (FUE), and others. On the basis of the application segment, the global market is segmented into Headhair Transplant, Eyebrow Transplant, Frontal Hairline Lowering or Reconstruction, and Others. On the basis of end-Users, Market is classified into Hospital, Tricology Clinics, Dermatological Clinics, and Others Americas, Europe, Asia Pacific, and the MEA regions are being categorized in the report. North America is the biggest market for hair transplants. North America equipped with scientific progressions, dexterous people, and superior healthcare infrastructure is one of the major causes. The European and North American markets have a massive portion of the market. The Asia-Pacific region is probable to develop at an extensive high CAGR by 2026. Browse the full “Hair Transplant Market By Surgery Method (Single Follicular Unit Transplantation (FUT), Follicular Unit Extraction (FUE) and Others), By Surgical Type (Headhair Transplant, Eyebrow Transplant, Frontal Hairline Lowering or Reconstruction and Others) By distribution channel (Hospital, Tricology Clinics, Dermatological Clinics, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2026” report at https://www.fnfresearch.com/hair-transplant-market-by-surgery-method-single-follicular-949 Key Insights from Primary Research As per our primary respondents, the global hair transplant market is set to grow annually at a rate of around 21.3%.It was established through primary research that the global hair transplant market was valued at around USD 5,612.23 Billion in 2019.The “Single Follicular Unit Transplantation (FUT)” category, on the basis of product segmentation, was the leading revenue-generating category in 2019.On the basis of surgery type segmentation, the “Head Hair Transplant” category was the leading revenue-generating category in 2019.Based on the region, North America was the leading revenue-generating category in 2019. The taxonomy of the Hair Transplant Market by its scope and segmentation is as follows: Global Hair Transplant Market: Surgery Method Segment Analysis Follicular Unit Transplantation (FUT)Follicular Unit Extraction (FUE)Others Global Hair Transplant Market: Surgery Type Segment Analysis Head hair TransplantEyebrow TransplantFrontal Hairline Lowering or ReconstructionOthers Global Hair Transplant Market: End-Users Segment Analysis HospitalTricology ClinicsDermatological ClinicsOthers Related Reports: Plasma Therapy Market: https://www.fnfresearch.com/plasma-therapy-market-type-pure-prp-leucocyte-rich-1279 Pneumonia Therapeutics Market: https://www.fnfresearch.com/pneumonia-therapeutics-market-by-product-type-drugs-branded Antibody Drug Conjugates Market: https://www.fnfresearch.com/antibody-drug-conjugates-market-by-drugs-adcetris-and Tissue Culture Reagents Market: https://www.fnfresearch.com/tissue-culture-reagents-market-by-product-40-70m-1253 Prebiotics Ingredients Market: https://www.fnfresearch.com/prebiotics-ingredients-market-by-application-food-beverages-agricultural-1231 About Facts & Factors (FnF Research): Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business. Follow Us LinkedIn: https://www.linkedin.com/company/fnfresearch Follow Us Twitter: https://twitter.com/fnfresearch Contact Us: Facts & Factors USA: +1-347-989-3985 Email: firstname.lastname@example.org Web: https://www.fnfresearch.com Blog: http://fnfnewsblog.com